Literature DB >> 27807238

Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Thomas Pietschmann1.   

Abstract

Chronic hepatitis C virus (HCV) infection causes severe liver disease and affects ca. 146 million individuals. Novel directly acting antivirals targeting HCV have revolutionized treatment. However, high costs limit access to therapy. Recently, several related drugs used in humans to treat allergies or as neuroleptics emerged as potent HCV cell entry inhibitors. Insights into their antiviral modes of action may increase opportunities for drug repurposing in hepatitis C and possibly other important human viral infections.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  cell entry; drug repurposing; fusion inhibitor; hepatitis C virus; infectious disease; ion channel inhibitors; membrane fusion

Mesh：

Substances：

Year:  2017        PMID： 27807238      PMCID： PMC5215334          DOI： 10.1128/JVI.01914-16

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  52 in total

1.  Screening for anti-HIV drugs that can combine virucidal and virustatic activities synergistically.

Authors:  A N Chakrabarty; M Mookerjee; S G Dastidar
Journal:  Int J Antimicrob Agents       Date:  2000-04       Impact factor: 5.283

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

3.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

4.  Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.

Authors:  Shanshan He; Billy Lin; Virginia Chu; Zongyi Hu; Xin Hu; Jingbo Xiao; Amy Q Wang; Cameron J Schweitzer; Qisheng Li; Michio Imamura; Nobuhiko Hiraga; Noel Southall; Marc Ferrer; Wei Zheng; Kazuaki Chayama; Juan J Marugan; T Jake Liang
Journal:  Sci Transl Med       Date:  2015-04-08       Impact factor: 17.956

Review 5.  From non-A, non-B hepatitis to hepatitis C virus cure.

Authors:  Jean-Michel Pawlotsky; Jordan J Feld; Stefan Zeuzem; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 6.  The structure and function of G-protein-coupled receptors.

Authors:  Daniel M Rosenbaum; Søren G F Rasmussen; Brian K Kobilka
Journal:  Nature       Date:  2009-05-21       Impact factor: 49.962

7.  Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus.

Authors:  Ana M Chamoun-Emanuelli; Eve-Isabelle Pécheur; Zhilei Chen
Journal:  Antiviral Res       Date:  2014-07-11       Impact factor: 5.970

8.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

9.  Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds.

Authors:  Zongyi Hu; Keng-Hsin Lan; Shanshan He; Manju Swaroop; Xin Hu; Noel Southall; Wei Zheng; T Jake Liang
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

Review 10.  Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Hepatol Int       Date:  2016-04-05       Impact factor: 9.029
View more
  6 in total

1.  Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.

Authors:  Zongyi Hu; Adam Rolt; Xin Hu; Christopher D Ma; Derek J Le; Seung Bum Park; Michael Houghton; Noel Southall; D Eric Anderson; Daniel C Talley; John R Lloyd; Juan C Marugan; T Jake Liang
Journal:  Cell Chem Biol       Date:  2020-05-07       Impact factor: 8.116

2.  Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.

Authors:  Adam Rolt; Derek Le; Zongyi Hu; Amy Q Wang; Pranav Shah; Marc Singleton; Emma Hughes; Andrés E Dulcey; Shanshan He; Michio Imamura; Takuro Uchida; Kazuaki Chayama; Xin Xu; Juan J Marugan; T Jake Liang
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226

3.  Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies.

Authors:  Ana C Carro; Luana E Piccini; Elsa B Damonte
Journal:  PLoS Negl Trop Dis       Date:  2018-08-09

4.  Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.

Authors:  José A Marrugal-Lorenzo; Ana Serna-Gallego; Judith Berastegui-Cabrera; Jerónimo Pachón; Javier Sánchez-Céspedes
Journal:  Sci Rep       Date:  2019-01-09       Impact factor: 4.379

5.  Structural Modifications and Biological Evaluations of Rift Valley Fever Virus Inhibitors Identified from Chemical Library Screening.

Authors:  Koushikul Islam; Marcus Carlsson; Per-Anders Enquist; Weixing Qian; Marko Marttila; Mårten Strand; Clas Ahlm; Magnus Evander
Journal:  ACS Omega       Date:  2022-02-16

Review 6.  Drug repositioning: A bibliometric analysis.

Authors:  Guojun Sun; Dashun Dong; Zuojun Dong; Qian Zhang; Hui Fang; Chaojun Wang; Shaoya Zhang; Shuaijun Wu; Yichen Dong; Yuehua Wan
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.